Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate cancer and the implications for body-iron stores
| Autor: | Walter Rayford, Raj Warrier, Tony Gauthier, Solo Kuvibidila |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Iron Transferrin receptor White People Pathology and Forensic Medicine Prostate cancer Internal medicine Receptors Transferrin medicine Humans Aged Retrospective Studies biology business.industry C-reactive protein Prostatic Neoplasms Cancer Anemia General Medicine Middle Aged medicine.disease Black or African American Ferritin Prostate-specific antigen Endocrinology Case-Control Studies Ferritins biology.protein Erythropoiesis Population study business |
| Zdroj: | Journal of Laboratory and Clinical Medicine. 144:176-182 |
| ISSN: | 0022-2143 |
| DOI: | 10.1016/j.lab.2004.03.017 |
| Popis: | The serum transferrin receptor (sTfR) is a sensitive indicator of iron-deficiency erythropoiesis that is not affected by inflammation. Concentrations of this molecule are inversely correlated with body-iron stores, and increased body-iron stores are associated with an increased risk of cancer of the liver and lungs. However, an association between iron status as assessed on the basis of sTfR and prostate cancer has not been previously investigated. We measured sTfR and serum ferritin by means of an enzyme immunoassay in 27 men with newly diagnosed, untreated prostate cancer and in 72 controls. Our study population ranged in age from 38 to 78 years. The mean serum ferritin concentration in men with prostate cancer was 44.8% lower than that in men without this tumor ( P.05). In contrast, the mean values of sTfR and sTfR/log serum ferritin were 32% and 60% higher, respectively, in men with prostate cancer than in those without this tumor ( P.05). Differences between groups persisted after we took into account inflammation (alpha 1-acid glycoprotein1 g/L, C-reactive protein10 mg/L; P.05). Among the entire study population and among men without inflammation, a higher percentage of subjects (29%-31%) than of controls (14%-22%) had sTfR values greater than 8 mg/L, suggestive of iron-deficiency erythropoiesis ( P.05). The odds ratios for men with prostate cancer to have sTfR values of less than 2.9 mg/L (suggestive of increased body-iron stores) was 0, compared with 1.745 to 3.65 for the same men to have sTfR values greater than 8 mg/L. sTfR was negatively correlated with log ferritin ( r = -.422, P.05) but did not correlate with tissue inflammation, tumor stage, or acute-phase proteins. It appears that prostate cancer is not associated with increased body-iron stores. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect